Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study
The Kuopio Osteoporosis Risk Factor and Prevention (OSTPRE) Study examines the risk factors of osteoporosis, the relationship of risk factors to bone density and fractures, as well as the possibility to prevent bone loss by administering certain hormones. The baseline postal enquiry in 1989 was sent to all the 14,220 women aged 47-56 years residing in the Kuopio Province, Finland. The questionnaire included questions about their gynaecological history, physical exercise and smoking habits, calcium intake, body weight and height, history of bone fractures, health disorders, their current and previous use of drugs, as well as their willingness to participate in bone densitometry and in a clinical hormone trial. The response rate was 92.8%. In all, 56% reported some previous use of female hormones. Strong contraindications for oestrogen replacement therapy were found in 9.3% of the women. Almost half of the respondents reported lack of regular physical exercise, 11.9% were smokers, and 17.0% reported a calcium intake from milk products of less than 500 mg daily. The incidence of fractures increased steadily with age. The incidence of premenopausal fractures within the last 10 years was 7.65 per 1000 person/years and that of postmenopausal fractures was 17.40 per 1000 person/years (P = 0.000). The effect of menopause on fracture incidence was stronger than the effect of a 5-year age increase. Of the respondents, 84.4% were willing to participate in bone densitometry and 68.3% for long-term prevention of osteoporosis with oestrogen.
osteoporosis risk factors perimenopausal women population study, Kuopio OSTPRE study bone density fracture prevention, menopause fracture incidence gynaecological history risk factors, perimenopausal bone loss calcium intake physical exercise, Tuppurainen Honkanen osteoporosis risk factor prevention study, postmenopausal fracture incidence estrogen replacement willingness, perimenopausal women bone health population-based postal survey, menopause effect fracture risk age-related bone loss, hormone replacement therapy contraindications perimenopausal screening, calcium intake smoking exercise osteoporosis risk perimenopausal
PMID 8231907 8231907 DOI 10.1016/0378-5122(93)90004-2 10.1016/0378-5122(93)90004-2
Cite this article
Tuppurainen, M., Honkanen, R., Kröger, H., Saarikoski, S., & Alhava, E. (1993). Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study. *Maturitas*, *17*(2), 89-100. https://doi.org/10.1016/0378-5122(93)90004-2
Tuppurainen M, Honkanen R, Kröger H, Saarikoski S, Alhava E. Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study. Maturitas. 1993;17(2):89-100. doi:10.1016/0378-5122(93)90004-2
Tuppurainen, M., et al. "Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study." *Maturitas*, vol. 17, no. 2, 1993, pp. 89-100.
Introduction: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) an...
Background: The aim of the present study was to investigate the health risks of excess body weight in the light of its protective effects on bone fragility.
Methods: Femoral neck and lumbar spine dua...
Perimenopause/Menopause > Bone Health > BMI and Osteoporosis RiskBone Health > Risk Factors > Weight and Body CompositionPerimenopause/Menopause > Metabolic Health > Obesity Comorbidities
Besides the natural progestin, progesterone, there are different classes of progestins, such as retroprogesterone (i.e. dydrogesterone), progesterone derivatives (i.e. medrogestone) 17alpha-hydroxypro...
OBJECTIVE: to assess the therapeutic efficacy and safety of oral estriol for the treatment of climacteric symptoms in postmenopausal women.
METHODS: 68 postmenopausal women with climacteric symptoms ...